Castle Biosciences, Inc. (CSTL) Balance Sheet
As of 2026-06-30 (10-Q), Castle Biosciences, Inc. (CSTL) reported total assets of $561.2M, total liabilities of $91.1M and shareholders' equity of $470.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $62.1M. Long-term debt: $10.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CSTLCastle Biosciences, Inc.Follow CSTL — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 98.8 | 409.9 | 329.6 | 122.9 | 98.8 | 119.7 | 116.7 | 62.1 | |
| Short-term investments | — | — | 0.0 | 135.7 | 144.3 | 169.9 | 171.6 | 197.9 | |
| Receivables | 14.6 | 12.8 | 17.3 | 23.5 | 38.3 | 51.2 | 43.4 | 48.3 | |
| Inventory | 1.2 | 2.2 | 2.0 | 4.0 | 7.9 | 8.1 | 10.3 | 10.6 | |
| Current assets | 116.7 | 429.6 | 353.7 | 292.3 | 295.6 | 360.2 | 361.1 | 341.1 | |
| Total assets | 119.7 | 439.3 | 462.6 | 447.3 | 453.3 | 531.2 | 578.6 | 561.2 | |
| Current liabilities | 15.3 | 20.9 | 24.9 | 36.1 | 47.7 | 49.4 | 68.7 | 56.5 | |
| Long-term debt | 19.3 | 0.0 | — | — | 0.0 | 10.0 | 10.1 | 10.1 | |
| Short-term debt | 5.8 | 0.0 | — | — | 0.0 | 0.3 | 0.4 | 2.9 | |
| Total liabilities | 34.6 | 23.6 | 50.8 | 48.2 | 62.1 | 75.4 | 107.7 | 91.1 | |
| Shareholders' equity | 85.1 | 415.7 | 411.7 | 399.2 | 391.3 | 455.8 | 470.9 | 470.0 |
USD millions · SEC XBRL
Castle Biosciences, Inc. — questions
- How much cash does Castle Biosciences, Inc. have?
- $62.1M in cash and cash equivalents as of 2026-06-30.
- How much debt does Castle Biosciences, Inc. have?
- $10.1M of long-term debt and $2.9M due within a year as of 2026-06-30.
- What are Castle Biosciences, Inc.'s total assets?
- $561.2M as of 2026-06-30.
- What is Castle Biosciences, Inc.'s shareholders' equity?
- $470.0M as of 2026-06-30.
Every figure on this page comes from Castle Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.